Effect of Zymosan and Zymosan-Plus-Minocycline Treatment on PET Measures of 11C-(R)-PK11195 Binding
| Treatment | |||||
| Data | None | Saline | Zymosan | Zymosan plus minocycline | Zymosan vs. zymosan plus minocycline P |
| ROI | |||||
| Lesion | 1.17 ± 05 | 1.13 ± 15 | 1.96 ± 33 | 1.58 ± 12 | 0.004 |
| Contralateral | 1.24 ± 01 | 1.14 ± 12 | 1.19 ± 17 | 1.19 ± 10 | 0.958 |
| Ipsilateral, ventrolateral | 1.01 ± 01 | 0.94 ± 07 | 1.26 ± 18 | 0.91 ± 11 | 0.0001 |
| Contralateral, ventrolateral | 1.04 ± 15 | 0.98 ± 13 | 0.89 ± 13 | 0.84 ± 10 | 0.351 |
| Experimental parameters | |||||
| n | 2 | 5 | 10 | 9 | |
| Body weight immediately before PET scan (g) | 278 ± 25 | 259 ± 15 | 254 ± 15 | 236 ± 11 | 0.011 |
| ID/BW (kBq/g) | 127 ± 11 | 153 ± 22 | 143 ± 27 | 143 ± 19 | 0.960 |
| SA (MBq/nmol) | 15 ± 05 | 29 ± 20 | 37 ± 23 | 42 ± 15 | 0.608 |
| IM/BW (pmol/g) | 9.5 ± 4.2 | 7.4 ± 3.9 | 8.2 ± 8.9 | 4.3 ± 3.3 | 0.269 |
| Activityref (g/mL) | 0.37 ± 04 | 0.36 ± 05 | 0.43 ± 11 | 0.45 ± 08 | 0.827 |
| Massref (pmol/mL) | 2.9 ± 1.5 | 2.3 ± 1.2 | 3.1 ± 3.1 | 1.5 ± 0.9 | 0.175 |
Activityref = reference region radioactivity/(ID/BW) 35–80 min after injection; ID/BW = injected dose per body weight; IM/BW = injected mass per body weight; Massref = reference region tracer mass concentration at 35–80 min after injection; SA = specific activity.
ROI values are 11C-(R)-PK11195 DVRs; all values are mean ± SD; P was calculated by 2-tailed t test.